Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)

Reports Q1 revenue $28.9M, consensus $11.5M. Cash, cash equivalents and marketable securities were $953.4M as of March 31, 2024 vs. $1.0B as of December 31, 2023. The cash position is expected to fund operations into late 2026. “Intellia continues to make outstanding progress across our pipeline of in vivo and ex vivo single-dose CRISPR-based therapies. With one ongoing and two soon-to-be-initiated pivotal Phase 3 trials, Intellia is undoubtedly at the forefront of a new era in medicine,” said CEO John Leonard. “…Building on our success with in vivo gene inactivation, we are excited to initiate the first-in-human study of NTLA-3001 for AATD this year, positioning us to be the first to clinically validate CRISPR-based gene insertion. We look forward to continuing our strong execution, with many notable milestones to mark the progress against our strategic priorities.”